Search results
Eli Lilly to buy bowel disease drug developer Morphic for $3.2 bln - ET HealthWorld | Pharma
The Economic Times· 1 day agoLondon: Eli Lilly will acquire Morphic Holding for $3.2 billion in cash, the companies said on...
Eli Lilly's popular drug Mounjaro stuck at Indian regulators' counter
Business Standard India· 6 days agoPharmaceutical firm Eli Lilly is still awaiting approval from India’s drug regulator to market its...
India Approves The Weight Loss & Diabetes Drugs: Everything You Need To Know
NDTV· 6 days agoEli Lilly and Co., the pharmaceutical company, has secured the first approvals for the import and
Lilly beefs up bowel disease drug portfolio with $3.2 billion Morphic deal, says report - CNBC TV18
CNBC TV18· 1 day agoLilly counts its IBD drug, Omvoh, among its future growth drivers, besides its blockbuster weight...
Lilly bolsters IBD portfolio with $3.2bn Morphic acquisition
Pharmaceutical Technology· 1 day agoGlobalData estimates that the Crohn’s and ulcerative colitis markets will be worth $25.5bn and...
US Regulator Approves Eli Lilly Drug For Early Alzheimer Treatment - News18
News18· 7 days agoThe US Food and Drug Administration (FDA) approved a drug made by Eli Lilly on Tuesday that is...
Eli Lilly’s donanemab wins FDA approval for Alzheimer’s disease
Pharmaceutical Technology· 7 days agoIn comparison, Leqembi has an annual price tag of $26,500 per year, and is currently infused every...
Novo, Lilly fall after Biden calls for cheaper obesity drugs
CNBC Awaaz· 7 days agoNovo Nordisk A/S and Eli Lilly & Co. shares fell Tuesday after US President Joe Biden continued his...
Lilly to buy Morphic in $3B bet on inflammation drug
BioPharma Dive· 1 day agoThe deal would hand Lilly an experimental pill that could one day rival Takeda's blockbuster medicine Entyvio as a treatment for inflammatory bowel...
Biogen completes $1.15bn HI-Bio acquisition to expand immunology presence
Pharmaceutical Technology· 6 days agoAs Eli Lilly’s Kisunla (donanemab) enters the Alzheimer's treatment space, its leading...